Multidrug resistance in Haemonchus contortus in sheep - can it be overcome?
Michal Babják
Institute of Parasitology of Slovak Academy of SciencesKošice, Slovak Republic
Profilo OrcidCerca questo autore su
, Alžbeta Königová
Institute of Parasitology of Slovak Academy of SciencesKošice, Slovak Republic
Profilo OrcidCerca questo autore su
, Michaela Komáromyová
Institute of Parasitology of Slovak Academy of SciencesKošice, Slovak Republic
Profilo OrcidCerca questo autore su
, Tetiana Kuzmina
- Institute of Parasitology of Slovak Academy of SciencesKošice, Slovak Republic
- Department of Parasitology, I. I. Schmalhausen Institute of Zoology NAS of UkraineKyiv, Ukraine
Profilo OrcidCerca questo autore su
, Pawel Nosal
Department of Zoology and Animal Welfare, University of Agriculture in KrakowKraków, Poland
Profilo OrcidCerca questo autore su
e Marián Várady
Institute of Parasitology of Slovak Academy of SciencesKošice, Slovak Republic
Profilo OrcidCerca questo autore su
19 dic 2023
INFORMAZIONI SU QUESTO ARTICOLO
Pubblicato online: 19 dic 2023
Pagine: 575 - 581
Ricevuto: 22 mag 2023
Accettato: 09 ott 2023
DOI: https://doi.org/10.2478/jvetres-2023-0057
Parole chiave
© 2023 Michal Babják et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Lethal dose (LD50), minimum inhibitory concentration (MIC) and mean larval development ±SD at MIC thresholds for the three classes of anthelmintics obtained from the in vitro larval development tests
| Drug | Larval development test | ||
|---|---|---|---|
| LD50 | MIC | L3 larvae (%) ± SD at MIC | |
| Thiabendazole | 0.37 | n.a. | 56.31 ± 5.19 |
| Ivermectin | 28.87 | 173.6 | 45.73 ± 6.32 |
| Levamisole | 0.10 | 1.0 | 0 ± 0 |
Results of the morphological identification of third-stage larvae before and after treatment with albendazole (ALB), ivermectin (IVM) and levamisole (LEV)
| Species | Before treatment (%) | After treatment (%) | ||
|---|---|---|---|---|
| ALB | IVM | LEV | ||
| 77 | 100 | 100 | — | |
| 13 | — | — | — | |
| 7 | — | — | — | |
| 3 | — | — | — | |
Mean hatching (in %) with standard deviation (SD) and mean of ED50 from the in vitro egg hatch test
| TBZ concentration (μg/mL) | Mean hatching (%) | ±SD |
|---|---|---|
| Control | 96.25 | 0.43 |
| 0.05 | 96.00 | 1.22 |
| 0.1 | 91.25 | 4.22 |
| 0.3 | 84.00 | 1.73 |
| 0.5 | 71.50 | 4.55 |
| 1 | 54.50 | 3.22 |
| Mean ED50 ± SD | 1.22 | 0.08 |
Results of the in vivo faecal egg count reduction test (FECRT): percent reduction 10 days after treatment in both phases of the trial
| Group (n = 10)/Treatment | Mean EPG ± SD | FECR(%) | ||
|---|---|---|---|---|
| Cabaret and Berrag formula (2004) (5) | Kochapakdee formula (1995)(16) | |||
| Phase 1 | G1 Albendazole single dose | |||
| D0 | 370 ± 205 | 0 | 0 | |
| D10 | 1,465 ± 1,482 | |||
| G2 Albendazole fasting dose | ||||
| D0 | 1,525 ± 1,212 | 16.90 | 13.70 | |
| D10 | 1,317 ± 986 | |||
| G3 Albendazole divided dose | ||||
| D0 | 710 ± 326 | 0 | 0 | |
| D10 | 1,400 ± 794 | |||
| G4 Albendazole double dose | ||||
| D0 | 605 ± 321 | 0 | 0 | |
| D10 | 1,680 ± 1,803 | |||
| G5 Ivermectin | ||||
| D0 | 350 ± 345 | 39.97 | 31.50 | |
| D10 | 240 ± 232 | |||
| Phase 2 | Levasmisole | |||
| D0 | 2,233 ± 2,045 | 100 | 100 | |
| D10 | 0 | |||
| Control | ||||
| D0 | 2,436 ± 1,239 | |||
| D10 | 2,297 ± 968 | |||